Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02582749 · ClinicalTrials.gov registry record · Phase 2
Androgen Deprivation Therapy +/- Radium-223 Dichloride in Metastatic Prostate Cancer With Bone Metastases
A Phase 2 study, sponsored by Ajjai Alva, MD.
- Terminated
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
NCT02582749 is a Phase 2 study that was terminated before completion, run by Ajjai Alva, MD. The registered enrollment target is 16 participants.
The verdict
NCT02582749, a Phase 2 study, was terminated before completion, sponsored by Ajjai Alva, MD.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
Study Summary
Newly diagnosed metastatic prostate cancer subjects with bone metastases will be accrued to this stratified randomized 2-arm Phase II trial. Subjects will be randomized 1:2 to ADT or ADT with Radium-223 dichloride respectively.
Interventions
- DRUG Bicalutamide
- DRUG LHRH agonist/antagonist
- RADIATION Radium-223 dichloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2016-04 |
| Est. Completion | 2017-09-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02582749
The ClinicalTrials.gov registry entry for NCT02582749 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ajjai Alva, MD, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Bicalutamide is the first listed.
NCT02582749 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02582749 about?
NCT02582749 is a clinical study titled "Androgen Deprivation Therapy +/- Radium-223 Dichloride in Metastatic Prostate Cancer With Bone Metastases". Newly diagnosed metastatic prostate cancer subjects with bone metastases will be accrued to this stratified randomized 2-arm Phase II trial. Subjects will be randomized 1:2 to ADT or ADT with Radium-223 dichloride respectively.
What is the current status of trial NCT02582749?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2016-04. Estimated completion is 2017-09-14.
What interventions are being tested in trial NCT02582749?
The interventions under investigation include: Bicalutamide (DRUG), LHRH agonist/antagonist (DRUG), Radium-223 dichloride (RADIATION).
Who is sponsoring clinical trial NCT02582749?
This trial is sponsored by Ajjai Alva, MD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.